AZD1390

SKU: orb1225705

Description

AZD1390 (AZD-1390) is a novel potent, selective, orally available and CNS penetrant ATM inhibitor with IC50 of 0.78 nM, displays >1,000-fold selectivity over closely related (PIKKs) and distant kinases; radiosensitises a panel of glioblastoma multiforme (GBM) cell lines and NCI-H2228 lung cells (IC50=3 nM); demonstrates potential in combination with radiation therapy for the treatment of brain tumors.Brain Cancer,Phase 1 Clinical(In Vivo):Median survival of mice treated with AZD1390 and radiation are significantly longer than untreated control mice (p=0.001). No overt signs of treatment toxicity are observed with small animal radiation research platform (SARRP) contrary to wholehead irradiated mice that seem to develop mucositis and difficulties drinking and eating at doses >10 Gy in combination with AZD1390.

Key Properties

• CAS Number: 2089288-03-7
• MW: 477.584
• Purity: >98% (HPLC)
• Formula: C₂₇H₃₂FN₅O₂
• SMILES: O=C(N1C(C)C)N(C)C2=C1C3=CC(C4=CC=C(OCCCN5CCCCC5)N=C4)=C(F)C=C3N=C2
• Target: ATM/ATR
• Solubility: DMSO: 20 mg/mL, Need ultrasonic and warming （ < 1 mg/ml refers to the product slightly soluble or insoluble )

Bioactivity

• In Vivo:
  Median survival of mice treated with AZD1390 and radiation are significantly longer than untreated control mice (p = 0.001). No overt signs of treatment toxicity are observed with small animal radiation research platform (SARRP) contrary to wholehead irradiated mice that seem to develop mucositis and difficulties drinking and eating at doses >10 Gy in combination with AZD1390.
  Read more...

Storage & Handling

• Storage: Storage temperature: -20°C. Stability: ≥ 2 years
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

AZD 1390 | AZD-1390

Quick Database Links

Gene Symbol

ATM/ATR